Daniel O'Reilly

8PUBLICATIONS
51CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Separation technologiesMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 12, 2026
Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington's disease pathogenesis in mice.

|Jul 21, 2026
Single-dose administration of therapeutic divalent siRNA targeting MECP2 prevents lethality in an MECP2 duplication mouse model.

|Mar 24, 2026
RNAi-mediated p38δ silencing mitigates anthracycline cardiotoxicity in female mice.

Katy A Trampel, Katherine Y Gross, Daniel O'Reilly

|Mar 18, 2026
Lowering the HTT1a transcript as an effective therapy for Huntington's disease in a knockin mouse model.

Aikaterini Smaragdi Papadopoulou, Julia Alterman, Christian Landles

|Dec 17, 2024
Chemical engineering of CRISPR-Cas systems for therapeutic application.

Halle M Barber, Adrian A Pater, Keith T Gagnon

|May 22, 2024
mRNA nuclear clustering leads to a difference in mutant huntingtin mRNA and protein silencing by siRNAs in vivo.

Sarah Allen, Daniel O'Reilly, Rachael Miller

Pageof 2

Frequent Collaborators

5 joint publications

Anastasia Khvorova

3 joint publications

Dimas Echeverria Moreno

3 joint publications

Ashley Summers

2 joint publications

Jillian Belgrad